EIF4EBP1 PHOSPHORYLATION

CI-VAR-00003443Explore in graph →CIViC 387

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastric Adenocarcinoma1
EIF4EBP1 PHOSPHORYLATION	Everolimus	Predictive	D	Supports Sensitivity Response	2	accepted	EID918 8 gastric cancer cell lines were treated with the MTOR inhibitor everolimus. Cell proliferation was effectively inhibited in 3 cell lines by everolimus. Phosphorylated EIF4EBP1 (T37/46, T70) levels we… (full text at CIViC) PMID 23340172 · Nishi et al., 2013 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
EIF4EBP1 PHOSPHORYLATION	Dactolisib + MTOR Kinase Inhibitor PP242 + WYE354Substitutes	Predictive	D	Supports Resistance	2	accepted	EID932 12 CRC cell lines were evaluated. 40% of these were intrinsically resistant to mTOR inhibition with BEZ235, PP242 or WYE354. mTOR independent phosphorylation of EIF4EBP1 (T37/46) was associated with …

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.